论文部分内容阅读
用已构建的mIL-21/pcDNA3.1重组质粒对H22细胞建立的小鼠肝癌模型进行基因治疗,观察IL-21对小鼠体内抗肿瘤免疫应答的影响及对小鼠生存的影响。采用BALB/c小鼠左腋皮下注射腹水型肝癌细胞株H22细胞建立小鼠移植肝癌模型,给荷瘤小鼠瘤体内注射mIL-21/pcDNA3.1进行基因治疗,MTT比色法检测IL-21对荷瘤小鼠T细胞增殖水平及NK细胞杀伤活性的影响,观察治疗后荷瘤小鼠生存情况及肿瘤生长情况的改变。病理检测结果显示,成功建立了小鼠移植型肝癌模型,MTT比色法显示基因治疗后小鼠T细胞增殖水平及NK细胞杀伤活性显著升高,荷瘤小鼠肿瘤生长速度减慢,生存期显著延长。IL-21基因治疗肝癌荷瘤小鼠可显著提高荷瘤小鼠体内抗肿瘤免疫应答水平,抑制肿瘤生长,延长荷瘤小鼠生存期。
H22 cells were established by mIL-21 / pcDNA3.1 recombinant plasmids. The effects of IL-21 on the anti-tumor immune response in mice and the effects on the mice survival were observed. The mouse model of transplanted hepatocellular carcinoma was established by subcutaneous injection of ascites hepatocellular carcinoma cell line H22 in BALB / c mice. The mIL-21 / pcDNA3.1 was injected into tumor-bearing mice for gene therapy. MTT assay was used to detect IL- 21 on tumor-bearing mice T cell proliferation and NK cell killing activity observed after treatment of tumor-bearing mice survival and tumor growth changes. The results of pathological examination showed that the mouse model of transplanted hepatocellular carcinoma was successfully established. The MTT assay showed that the proliferation of T cells and the cytotoxicity of NK cells were significantly increased after the gene therapy. The tumor growth rate of tumor-bearing mice was slow, Significantly longer. IL-21 gene therapy in liver cancer-bearing mice can significantly increase the anti-tumor immune response in tumor-bearing mice, inhibit tumor growth, and prolong the survival of tumor-bearing mice.